Lorundrostat Shows Promise for Resistant Hypertension Lorundrostat acts by directly inhibiting aldosterone synthesis while sparing other adrenal steroid pathways, potentially overcoming limitations of mineralocorticoid receptor antagonists such as compensatory aldosterone elevation and poor tolerability Investigators highlighted the drug’s potential to expand therapeutic options for patients
Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled . . . Decreasing aldosterone production via inhibition of aldosterone synthase, rather than blocking the mineralocorticoid receptor, may avoid these adverse effects Lorundrostat is a selective inhibitor of aldosterone synthase currently under investigation
Lorundrostat Lowers Blood Pressure Compared with Placebo at 12 Weeks Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented at the American College of Cardiology’s Annual Scientific Session (ACC 25)
Lorundrostat - Wikipedia Lorundrostat (developmental name MLS 101) is an aldosterone synthase inhibitor developed by Mineralys Therapeutics for high blood pressure